By Dennis Ford, Founder & CEO, Life Science Nation (LSN)
As part of Life Science Nation’s series on converting scientific innovation into investable signal, the focus now shifts to economic risk. After market, technical, regulatory, and execution risks are addressed, the next question becomes whether the product creates enough real-world value to support sustainable adoption.
Economic risk is where value must become viability. Even if a product works and can be approved, it must still fit within the financial realities of healthcare systems, payers, providers, and patients.
This article examines how companies define and validate their economic case through value proposition, pricing strategy, reimbursement pathways, health economic impact, and competitive positioning.
From proving clinical benefit to demonstrating sustainable commercial value, this layer of the De-Risk Stack determines whether innovation can succeed not just scientifically—but economically.
Even if a product works and can be approved, it must still make economic sense within the healthcare systems that will use and pay for it.
Economic risk is often treated as secondary to clinical and technical considerations. In practice, it frequently determines whether adoption occurs at scale and whether the business is sustainable.
The core question is whether the product creates value that is recognized, fundable, and durable.
This begins with the value proposition. The product must deliver a meaningful clinical or economic benefit that is understood by payers, providers, and health systems. The value must be evidence-based, not speculative.
Pricing strategy must then align with that value while remaining acceptable within system constraints. A product priced far above perceived value will struggle; a product priced too low to sustain the business simply moves risk downstream.
A viable reimbursement pathway is essential. This means understanding existing codes, coverage policies, and benefit designs, and knowing whether the product fits into current structures or requires new ones to be established.
Health economic impact and budget impact analyses translate the value story into system terms. Products that improve outcomes at acceptable or lower cost are easier to adopt; products that create near-term budget spikes can face resistance even if they are cost-effective in the long run.
Adoption economics define why providers would choose this product. That includes workflow impact, revenue implications, and perceived risk for clinicians and institutions. Competitive economics compare the full economic case—including acquisition cost, utilization, and downstream impact—against available alternatives.
Economic risk is resolved when the product creates clear, measurable, and fundable value within the actual economic and budget constraints of the system.
Core Elements of Economic Risk
- Value proposition
- Pricing strategy
- Reimbursement pathway
- Health economic impact
- Budget impact
- Adoption economics
- Competitive economics
Next in the series: Financing Risk — From Opportunity to Investable Campaign
Previous Articles：
Next Phase Newsletter 